CD34 and myelofibrosis: This validates combinatorial targeting of stem cell (e.g., CD34) and megakaryocyte (e.g., G6B) surface antigens, e.g., with bi-specific antibody therapies as a potential strategy worthy of further investigation for selective ablation of the myelofibrosis clone.